Diabetic kidney disease: act now or pay later

被引:33
作者
Atkins, R. C.
Zimmet, P.
机构
关键词
RISK-FACTORS; TYPE-2; NEPHROPATHY; PREVALENCE; MICROALBUMINURIA; IRBESARTAN; MELLITUS; OUTCOMES; OBESITY;
D O I
10.1093/ndt/gfp757
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
引用
收藏
页码:331 / 333
页数:3
相关论文
共 28 条
[1]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[2]  
[Anonymous], 2007 ANN DAT REP ALT
[3]   Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? [J].
Bilous, R. .
DIABETIC MEDICINE, 2008, 25 :25-29
[4]   Novel therapies of diabetic nephropathy [J].
Burney, Basil O. ;
Kalaitzidis, Rigas G. ;
Bakris, George L. .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (02) :107-111
[5]   The rising prevalence of diabetes and impaired glucose tolerance - The Australian diabetes, obesity and lifestyle study [J].
Dunstan, DW ;
Zimmet, PZ ;
Welborn, TA ;
de Courten, MP ;
Cameron, AJ ;
Sicree, RA ;
Dwyer, T ;
Colagiuri, S ;
Jolley, D ;
Knuiman, M ;
Atkins, R ;
Shaw, JE .
DIABETES CARE, 2002, 25 (05) :829-834
[6]   Effect of a multifactorial intervention on mortality in type 2 diabetes [J].
Gaede, Peter ;
Lund-Andersen, Henrik ;
Parving, Hans-Henrik ;
Pedersen, Oluf .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591
[7]   10-year follow-up of intensive glucose control in type 2 diabetes [J].
Holman, Rury R. ;
Paul, Sanjoy K. ;
Bethel, M. Angelyn ;
Matthews, David R. ;
Neil, H. Andrew W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1577-1589
[8]  
International Diabetes Federation and International Society of Nephrology, 2003, DIAB KIDN DIS TIM AC
[9]   Global burden of diabetes, 1995-2025 - Prevalence, numerical estimates, and projections [J].
King, H ;
Aubert, RE ;
Herman, WH .
DIABETES CARE, 1998, 21 (09) :1414-1431
[10]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860